Holen Sie sich die Stockscreener-App
5.83
2.18%
-0.13
Handel nachbörslich:
5.82
-0.010
-0.17%
Schlusskurs vom Vortag:
$5.96
Offen:
$6.54
24-Stunden-Volumen:
99,164
Relative Volume:
0.49
Marktkapitalisierung:
$297.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-103.21M
KGV:
-
EPS:
-
Netto-Cashflow:
$-26.70M
1W Leistung:
-4.11%
1M Leistung:
-22.27%
6M Leistung:
-33.07%
1J Leistung:
-18.23%
1-Tages-Spanne:
$5.60
$6.54
1-Wochen-Bereich:
$5.60
$6.55
52-Wochen-Spanne:
$4.42
$18.40
Engene Holdings Inc Stock (ENGN) Company Profile
Firmenname
Engene Holdings Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Vergleichen Sie ENGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
5.83 | 297.19M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Holdings Inc Aktie (ENGN) Neueste Nachrichten
Engene Holdings Faces Regulatory Challenges and Business Risks Amid Clinical Trial Hurdles - TipRanks
enGene Holdings Inc. (ENGN) Upgraded to Strong Buy: Here's Why - MSN
enGene Holdings inks $100M share sale deal with Jefferies - Investing.com
EnGene : Material Agreement Form 8 K - Marketscreener.com
Form 424B5 enGene Holdings Inc. - StreetInsider.com
EnGene Holdings Inc. Reports Earnings Results for the Full Year Ended October 31, 2024 - Marketscreener.com
enGene Reports Full Year 2024 Financial Results and Provides a Business Update - BioSpace
(ENGN) Technical Pivots with Risk Controls - Stock Traders Daily
enGene Holdings Inc. (ENGN) reports earnings - Quartz
enGene (NASDAQ:ENGN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
enGene Reports Promising 71% Response Rate in Bladder Cancer Trial, Strong $298M Cash Position - StockTitan
enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook (NASDAQ:ENGN) - Seeking Alpha
Here's Why enGene Holdings Inc. (ENGN) is Poised for a Turnaround After Losing -16.9% in 4 Weeks - MSN
(ENGN) Investment Analysis - Stock Traders Daily
Point72 Asset Management L.P. Has $4.38 Million Holdings in enGene Holdings Inc. (NASDAQ:ENGN) - MarketBeat
enGene’s (ENGN) Market Outperform Rating Reiterated at JMP Securities - Defense World
enGene's (ENGN) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Critical Comparison: OKYO Pharma (NASDAQ:OKYO) versus enGene (NASDAQ:ENGN) - Defense World
Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) - Defense World
Raymond James Initiates Coverage of enGene Holdings (ENGN) with Outperform Recommendation - MSN
enGene (NASDAQ:ENGN) Earns Outperform Rating from Analysts at Raymond James - MarketBeat
Recent uptick might appease enGene Holdings Inc. (NASDAQ:ENGN) institutional owners after losing 4.2% over the past year - Simply Wall St
enGene to Participate in Upcoming Investor Conferences - Vulcan Advocate
enGene Holdings to Present Cancer Treatment Updates at Major Healthcare Conferences - StockTitan
enGene (NASDAQ:ENGN) Coverage Initiated at JMP Securities - MarketBeat
JMP bullish on Engene stock as non-viral bladder cancer therapy gains traction By Investing.com - Investing.com South Africa
JMP bullish on Engene stock as non-viral bladder cancer therapy gains traction - Investing.com India
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
(ENGN) Trading Advice - Stock Traders Daily
With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners - Yahoo Finance
Blue Owl Capital Holdings LP Increases Stake in enGene Holdings Inc - GuruFocus.com
enGene files $300M mixed securities shelf - TipRanks
enGene Holdings Inc. (NASDAQ:ENGN) Receives $33.67 Consensus PT from Brokerages - MarketBeat
How the (ENGN) price action is used to our Advantage - Stock Traders Daily
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - BioSpace
enGene to Present Breakthrough Cancer Therapy at Guggenheim Healthcare Conference - StockTitan
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares - Investing.com Australia
Forbion growth opportunities fund acquires $4.99m in Engene Holdings shares By Investing.com - Investing.com South Africa
FY2024 EPS Estimates for enGene Boosted by Leerink Partnrs - MarketBeat
EnGene Announces $60 Million Private Placement Financing - Marketscreener.com
enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Growth in Short Interest - MarketBeat
enGene secures $60 million in private placement By Investing.com - Investing.com Canada
enGene Announces $60 Million Private Placement Financing - citybiz
Why enGene Holdings Stock Is Trading Higher - Benzinga
enGene secures $60 million in private placement - Investing.com
Finanzdaten der Engene Holdings Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Engene Holdings Inc-Aktie (ENGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 29 '23 |
Buy |
9.06 |
10,020 |
90,771 |
2,017,820 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 28 '23 |
Buy |
7.69 |
5,050 |
38,827 |
2,007,800 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Dec 27 '23 |
Buy |
7.17 |
2,750 |
19,711 |
2,002,750 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):